DiaMedica Therapeutics (DMAC) Competitors

Clene (NASDAQ:CLNN) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Which has higher valuation & earnings, CLNN or DMAC?

DiaMedica Therapeutics has lower revenue, but higher earnings than Clene. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$470 thousand	171.79	-$29.92 million	-$0.39	-2.64
DiaMedica Therapeutics	N/A	N/A	-$13.68 million	-$0.59	-5.32

Does the MarketBeat Community favor CLNN or DMAC?

DiaMedica Therapeutics received 39 more outperform votes than Clene when rated by MarketBeat users. However, 73.44% of users gave Clene an outperform vote while only 60.99% of users gave DiaMedica Therapeutics an outperform vote.

Company	Underperform	Outperform
Clene	Outperform Votes 47 73.44%	Underperform Votes 17 26.56%
DiaMedica Therapeutics	Outperform Votes 86 60.99%	Underperform Votes 55 39.01%

Do insiders and institutionals have more ownership in CLNN or DMAC?

5.9% of Clene shares are owned by institutional investors. Comparatively, 28.1% of DiaMedica Therapeutics shares are owned by institutional investors. 26.6% of Clene shares are owned by insiders. Comparatively, 6.5% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has more volatility & risk, CLNN or DMAC?

Clene has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500.

Does the media favor CLNN or DMAC?

In the previous week, Clene had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 2 mentions for Clene and 1 mentions for DiaMedica Therapeutics. Clene's average media sentiment score of 0.94 beat DiaMedica Therapeutics' score of 0.00 indicating that Clene is being referred to more favorably in the media.

Company	Overall Sentiment
Clene	Positive
DiaMedica Therapeutics	Neutral

Is CLNN or DMAC more profitable?

DiaMedica Therapeutics has a net margin of 0.00% compared to Clene's net margin of -5,151.64%. DiaMedica Therapeutics' return on equity of -46.58% beat Clene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-5,151.64%	-4,043.36%	-112.21%
DiaMedica Therapeutics	N/A	-46.58%	-43.51%

Do analysts recommend CLNN or DMAC?

Clene currently has a consensus target price of $10.33, indicating a potential upside of 903.24%. DiaMedica Therapeutics has a consensus target price of $10.00, indicating a potential upside of 218.47%. Given Clene's stronger consensus rating and higher possible upside, research analysts plainly believe Clene is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
DiaMedica Therapeutics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Clene beats DiaMedica Therapeutics on 10 of the 17 factors compared between the two stocks.